Type 1 Diabetes News and Research RSS Feed - Type 1 Diabetes News and Research

Type 1 diabetes, formerly called juvenile diabetes or insulin-dependent diabetes, is usually first diagnosed in children, teenagers, or young adults. In this form of diabetes, the beta cells of the pancreas no longer make insulin because the body’s immune system has attacked and destroyed them. Treatment for type 1 diabetes includes taking insulin shots or using an insulin pump, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.
Scientists develop implantable 'artificial pancreas' to help control blood sugar in diabetes patients

Scientists develop implantable 'artificial pancreas' to help control blood sugar in diabetes patients

Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the ACS journal Industrial & Engineering Chemistry Research the development of an implantable "artificial pancreas" that continuously measures a person's blood sugar, or glucose, level and can automatically release insulin as needed. [More]
Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Both spouses and first-degree relatives of patients with celiac disease are at increased risk of nonceliac autoimmune disease, according to a study in the July issue of Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. This risk represents a mixture of genetic, environmental and ascertainment bias mechanisms. [More]
Exhausted army of immune cells may damage the very body they are supposed to protect

Exhausted army of immune cells may damage the very body they are supposed to protect

An 'exhausted' army of immune cells may not be able to fight off infection, but if its soldiers fight too hard they risk damaging the very body they are meant to be protecting, suggests new research from the University of Cambridge. [More]
Perle Bioscience announces enrollment for Phase 3 trial of combination therapy in type 1 diabetics

Perle Bioscience announces enrollment for Phase 3 trial of combination therapy in type 1 diabetics

Perle Bioscience, Inc. announces enrollment for the Insulin Independence Trial (IIT). This trial is the first and only Phase 3 trial to test a combination therapy in type 1 diabetics. [More]
New 'smart insulin patch' could help patients suffering from diabetes

New 'smart insulin patch' could help patients suffering from diabetes

Painful insulin injections could become a thing of the past for the millions of Americans who suffer from diabetes, thanks to a new invention from researchers at the University of North Carolina and NC State, who have created the first "smart insulin patch" that can detect increases in blood sugar levels and secrete doses of insulin into the bloodstream whenever needed. [More]
Paediatric outpatient study compares effectiveness of three alternative treatments for type 1 diabetes

Paediatric outpatient study compares effectiveness of three alternative treatments for type 1 diabetes

A Montréal research team, co-supervised by Dr. Rémi Rabasa-Lhoret from the IRCM and Dr. Laurent Legault from the Montreal Children's Hospital, undertook the first paediatric outpatient study to compare three alternative treatments for type 1 diabetes. [More]
Catalan researchers first to use liposomes to fight against diabetes

Catalan researchers first to use liposomes to fight against diabetes

For the first time liposomes that imitate cells in the process of natural death have been used to treat Diabetes. Researchers at Germans Trias Research Institute (at UAB-Campus of International Excellence Sphere) generated liposomes in collaboration with professionals from the ICN2. PLOS ONE Journal publishes the work. [More]
Researchers pinpoint gene that may solve the root cause of diabetes

Researchers pinpoint gene that may solve the root cause of diabetes

Professor Jeffery Tessem has pinpointed a gene that may help solve a riddle at the root of diabetes, the high-blood-sugar disease affecting 400 million people worldwide. [More]
BioLineRx's BL-9020 antibody holds promise in treating Type 1 diabetes

BioLineRx's BL-9020 antibody holds promise in treating Type 1 diabetes

Type 1 diabetes, which usually appears in children and adolescents, affects over 30 million people worldwide. Resulting from an auto-immune reaction that destroys the pancreatic beta cells that produce insulin, the disease leads to pathologically high levels of sugar in the blood and urine, resulting in high rates of morbidity and mortality. The current treatment for Type 1 diabetes is lifetime administration of insulin by injection. [More]
Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston. [More]
Study addresses children's basic perspectives on living with Type 1 diabetes

Study addresses children's basic perspectives on living with Type 1 diabetes

If a picture is worth a thousand words, UF Health Type 1 diabetes researchers and their colleagues have tapped into an encyclopedia, revealing new insights into how young people cope with the disease. [More]
FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

The U.S. Food and Drug Administration (FDA) has approved Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog® (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes, Eli Lilly and Company announced today. Humalog U-200 KwikPen marks the first FDA approval of a concentrated mealtime insulin analog. [More]
New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating the range of treatment options represented in Lilly's diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston. [More]
Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9. [More]
Treatment outcomes in type 1 diabetes could be improved across all age groups

Treatment outcomes in type 1 diabetes could be improved across all age groups

In a sweeping analysis assessing the current state of diabetes treatment in the U.S., T1D Exchange researchers conclude that there remains considerable room for improving treatment outcomes in type 1 diabetes across all age groups, but especially for adolescents and young adults. [More]

Continuous glucose monitoring using real-time CGM helps better manage diabetes

Patients with insulin-dependent diabetes can better control their HbA1c value with a combination of blood glucose self-monitoring (BGSM) and continuous interstitial glucose monitoring (CGM) using a real-time measurement device (real-time CGM) than with BGSM alone without severe or serious hypoglycaemia occurring more frequently. [More]

Tandem Diabetes Care announces release of t:flex Insulin Pump

Tandem Diabetes Care, Inc., a medical device company and manufacturer of the t:slim Insulin Pump, today announced that it is now taking orders for the t:flex Insulin Pump, with shipments planned to begin in June. The 480-unit t:flex Pump, cleared by the U.S. Food and Drug Administration in January 2015, is the largest capacity insulin pump currently offered in the United States. [More]
Regulatory T cells can cure inflammatory diseases, shows research

Regulatory T cells can cure inflammatory diseases, shows research

Scientists at The University of Manchester have made an important discovery about an immune cell which is already being used in immunotherapy to treat diseases such as type I diabetes. [More]
Major breakthrough in understanding development of type 1 diabetes

Major breakthrough in understanding development of type 1 diabetes

Joslin researchers have uncovered the action of a gene that regulates the education of T cells, providing insight into how and why the immune system begins mistaking the body's own tissues for targets. The gene, Clec16a, is one of a suite of genes associated with multiple autoimmune disorders, suggesting it is fundamental to the development of autoimmunity. [More]
JDRF, Lilly partner to make life better for people with type 1 diabetes

JDRF, Lilly partner to make life better for people with type 1 diabetes

JDRF, the leading global organization funding type 1 diabetes (T1D) research, and Eli Lilly and Company, a global leader in diabetes care announced a two-year partnership that will provide $1.8 Million in support of JDRF's mission to improving the lives of people with T1D. [More]
Advertisement
Advertisement